238 related articles for article (PubMed ID: 17154180)
1. EphA2 overexpression is associated with angiogenesis in ovarian cancer.
Lin YG; Han LY; Kamat AA; Merritt WM; Landen CN; Deavers MT; Fletcher MS; Urbauer DL; Kinch MS; Sood AK
Cancer; 2007 Jan; 109(2):332-40. PubMed ID: 17154180
[TBL] [Abstract][Full Text] [Related]
2. EphA2 expression is associated with aggressive features in ovarian carcinoma.
Thaker PH; Deavers M; Celestino J; Thornton A; Fletcher MS; Landen CN; Kinch MS; Kiener PA; Sood AK
Clin Cancer Res; 2004 Aug; 10(15):5145-50. PubMed ID: 15297418
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical expression of angiogenic cytokines in childhood Hodgkin lymphoma.
Citak EC; Oguz A; Karadeniz C; Akyurek N
Pathol Res Pract; 2008; 204(2):89-96. PubMed ID: 18207652
[TBL] [Abstract][Full Text] [Related]
4. Cathepsin D in ovarian cancer: prognostic value and correlation with p53 expression and microvessel density.
Lösch A; Schindl M; Kohlberger P; Lahodny J; Breitenecker G; Horvat R; Birner P
Gynecol Oncol; 2004 Feb; 92(2):545-52. PubMed ID: 14766246
[TBL] [Abstract][Full Text] [Related]
5. Expression of urokinase plasminogen activator and its receptor in advanced epithelial ovarian cancer patients.
Wang L; Madigan MC; Chen H; Liu F; Patterson KI; Beretov J; O'Brien PM; Li Y
Gynecol Oncol; 2009 Aug; 114(2):265-72. PubMed ID: 19450871
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of matrix metalloproteinase-9 (MMP-9) in epithelial ovarian cancer.
Sillanpää S; Anttila M; Voutilainen K; Ropponen K; Turpeenniemi-Hujanen T; Puistola U; Tammi R; Tammi M; Sironen R; Saarikoski S; Kosma VM
Gynecol Oncol; 2007 Feb; 104(2):296-303. PubMed ID: 17034838
[TBL] [Abstract][Full Text] [Related]
7. Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer.
Lengyel E; Schmalfeldt B; Konik E; Späthe K; Härting K; Fenn A; Berger U; Fridman R; Schmitt M; Prechtel D; Kuhn W
Gynecol Oncol; 2001 Aug; 82(2):291-8. PubMed ID: 11531282
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer.
Landen CN; Lu C; Han LY; Coffman KT; Bruckheimer E; Halder J; Mangala LS; Merritt WM; Lin YG; Gao C; Schmandt R; Kamat AA; Li Y; Thaker P; Gershenson DM; Parikh NU; Gallick GE; Kinch MS; Sood AK
J Natl Cancer Inst; 2006 Nov; 98(21):1558-70. PubMed ID: 17077358
[TBL] [Abstract][Full Text] [Related]
9. Thrombospondin-1 expression in epithelial ovarian carcinoma: association with p53 status, tumor angiogenesis, and survival in platinum-treated patients.
Alvarez AA; Axelrod JR; Whitaker RS; Isner PD; Bentley RC; Dodge RK; Rodriguez GC
Gynecol Oncol; 2001 Aug; 82(2):273-8. PubMed ID: 11531279
[TBL] [Abstract][Full Text] [Related]
10. [Matrix metalloproteinase-2 and angiogenesis in gastric cancer].
Cai H; Kong ZR; Chen HM
Ai Zheng; 2002 Jan; 21(1):25-8. PubMed ID: 12500392
[TBL] [Abstract][Full Text] [Related]
11. Serous and mucinous ovarian tumors express different profiles of MMP-2, -7, -9, MT1-MMP, and TIMP-1 and -2.
Brun JL; Cortez A; Commo F; Uzan S; Rouzier R; Daraï E
Int J Oncol; 2008 Dec; 33(6):1239-46. PubMed ID: 19020757
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of stromal metalloproteinase-2 in ovarian adenocarcinoma and its relation to carcinoma progression.
Torng PL; Mao TL; Chan WY; Huang SC; Lin CT
Gynecol Oncol; 2004 Feb; 92(2):559-67. PubMed ID: 14766248
[TBL] [Abstract][Full Text] [Related]
13. Mast cell density, angiogenesis, blood clotting, and prognosis in women with advanced ovarian cancer.
Chan JK; Magistris A; Loizzi V; Lin F; Rutgers J; Osann K; DiSaia PJ; Samoszuk M
Gynecol Oncol; 2005 Oct; 99(1):20-5. PubMed ID: 16055178
[TBL] [Abstract][Full Text] [Related]
14. [Relationship between expression of matrix metalloproteinase (MMP-9) and tumor angiogenesis, cancer cell proliferation, invasion, and metastasis in invasive carcinoma of cervix].
Jiang ZQ; Zhu FC; Qu JY; Zheng X; You CL
Ai Zheng; 2003 Feb; 22(2):178-84. PubMed ID: 12600296
[TBL] [Abstract][Full Text] [Related]
15. Correlation of tumor- and stromal-derived MT1-MMP expression with progression of human ovarian tumors in SCID mice.
Drew AF; Blick TJ; Lafleur MA; Tim EL; Robbie MJ; Rice GE; Quinn MA; Thompson EW
Gynecol Oncol; 2004 Dec; 95(3):437-48. PubMed ID: 15581944
[TBL] [Abstract][Full Text] [Related]
16. The clinical significance of EphA2 and Ephrin A-1 in epithelial ovarian carcinomas.
Han L; Dong Z; Qiao Y; Kristensen GB; Holm R; Nesland JM; Suo Z
Gynecol Oncol; 2005 Nov; 99(2):278-86. PubMed ID: 16061279
[TBL] [Abstract][Full Text] [Related]
17. [Elevated expression of matrix metalloproteinase-9, and fibronectin concentration in recurrent epithelial ovarian cancer].
Demeter A; Szirmai K; Oláh J; Papp Z; Jeney A
Orv Hetil; 2004 Aug; 145(31):1617-24. PubMed ID: 15384859
[TBL] [Abstract][Full Text] [Related]
18. [Expression of KiSS-1, matrix metalloproteinase-9, nuclear factor-kappaBp65 in ovarian tumour].
Gao GL; Liu LD; Zou XS; Chen WX
Zhonghua Fu Chan Ke Za Zhi; 2007 Jan; 42(1):34-8. PubMed ID: 17331419
[TBL] [Abstract][Full Text] [Related]
19. The expression of matrix metalloproteinases-2 and -9 and their tissue inhibitor 2 in pancreatic ductal and ampullary carcinoma and their relation to angiogenesis and clinicopathological parameters.
Giannopoulos G; Pavlakis K; Parasi A; Kavatzas N; Tiniakos D; Karakosta A; Tzanakis N; Peros G
Anticancer Res; 2008; 28(3B):1875-81. PubMed ID: 18630474
[TBL] [Abstract][Full Text] [Related]
20. [Expression of EphA2 and EphrinA1 in human renal cell carcinoma and its relationship with angiogenesis].
Xu JS; Zhang JX; Geng TH; Wang YF; Wang XL; Zuo LF
Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):438-41. PubMed ID: 19950554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
